; (8) during the 115th Congress, Public Law 115–327 reauthorized a sickle cell disease prevention and treatment demonstration program and provided for sickle cell research, surveillance, prevention, and treatment; (9) following the enactment of Public Law 115–327 , the National Institutes of Health launched the Cure Sickle Cell Initiative aimed at bringing genetic therapies into first-in-human clinical trials within five years and moving newly developed genetic therapies, including gene-editing approaches, into clinical research; (10) communication of a screening result consistent with sickle cell trait should always be accompanied by appropriate counseling on the implications, provided by an individual with adequate training and understanding of the information; (11) the limited research on the communication of sickle cell trait test results to patients demonstrates that there is a high prevalence of misleading information being communicated during counseling sessions for sickle cell trait following newborn screening by clinicians; and (12) no studies have examined whether information on sickle cell trait test results is being accurately transmitted to an individual, whether by a family member or health care provider, prior to a person’s reproductive years. 22402. Sense of Congress Congress— (1) recognizes the importance of ensuring that people in the United States can make informed decisions as a result of awareness of their sickle cell trait status; (2) recognizes the ongoing challenges in addressing health outcomes among people with sickle cell trait and sickle cell disease; (3) recognizes the importance of the development of, and access to, new treatments for sickle cell disease